ImmunityBio, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $113.3M | $14.7M | $622,000 | $240,000 | $934,000 |
| Operating income | -$256.0M | -$344.2M | -$362.2M | -$351.3M | -$330.3M |
| Operating expenses | — | $358.9M | $362.9M | $351.5M | $331.2M |
| Cost of revenue | $753,000 | $0 | $0 | $0 | — |
| Cash from operations | -$304.9M | -$391.2M | -$366.8M | -$337.5M | -$274.4M |
| Capital expenditure | $3.8M | $6.9M | $30.6M | $78.2M | $33.6M |
| Free cash flow | -$308.8M | -$398.1M | -$397.3M | -$415.7M | -$308.0M |
| Share repurchases | — | — | — | — | $0 |
| Impairments | $14.0M | $0 | $0 | $1.3M | $0 |
| Total assets | $501.9M | $382.9M | $504.5M | $362.4M | $468.9M |
| Total liabilities | $1.0B | $871.1M | $1.1B | $812.2M | $712.8M |
Shares outstanding 1.0B · Free float 66.8%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.